| 词条 | Mikhail Blagosklonny |
| 释义 |
|name = Mikhail Blagosklonny |image = |image_size = |caption = |birth_date = |birth_place = |field = Anti-aging medicine, oncology |work_institutions = {{plainlist|1=
}} |alma_mater = First Pavlov State Medical University of St. Peterburg |education = |website= }}Mikhail Blagosklonny is a scientist who studies cancer and aging. He is a professor of oncology at the Roswell Park Cancer Institute in Buffalo, New York.[1] CareerBlagosklonny earned both his M.D. in internal medicine and his PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg.{{citation needed|date=November 2017}} He was appointed associate professor of medicine at New York Medical College, Valhalla, NY in 2002 before taking a position as a senior scientist at Ordway Research Institute (Albany, New York). Blagosklonny held this position until 2009, when he was appointed professor of oncology at Roswell Park Cancer Institute.[1] Blagosklonny's research interests include cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging (biogerontology) and anti-aging drugs.[2] Rapamycin and agingBlagosklonny has formulated a hypothesis about the possible role of TOR signaling in aging and cancer and proposed using rapamycin, a popular cancer drug as a possible treatment for life extension.[3] He advocates for rapamycin use in longevity research.[4] Editorial activitiesBlagosklonny is editor-in-chief of Aging,[5] Cell Cycle,[6] and Oncotarget.[7] In addition, he is associate editor of Cancer Biology & Therapy[8] and a member of the editorial board of Cell Death & Differentiation.[9] The peer review process employed by Oncotarget has been criticized by Jeffrey Beall,[10] a university librarian and expert on predatory open access publishing, who also included Oncotarget and Aging on his list of "potential, possible, or probable predatory scholarly open-access journals"[11] in July 2015.[10] Further reports on Beall's blog suggest that the substandard peer review processes for these journals are used by their respective editors-in-chief to entice prospective authors to include references to Blagosklonny's own publications in their articles (following the peer review), thereby raising his personal citation impact.[12] References1. ^1 {{citation | date = May 2009 | doi = 10.4161/cbt.8.9.8899 | issue = 9 | journal = Cancer Biology & Therapy | pages = 753–752 | title = Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute | volume = 8}} {{authority control}}{{DEFAULTSORT:Blagosklonny, Mikhail}}2. ^{{Cite journal|date=May 2009|title=Distinguished physician-scientist, Dr. Mikhail Blagosklonny, joins Roswell Park Cancer Institute|journal=Cancer Biology & Therapy|volume=8|issue=9|pages=753–752|doi=10.4161/cbt.8.9.8899}} 3. ^{{cite journal |first=David|last=Stipp|url=http://www.nature.com/scientificamerican/journal/v306/n1/full/scientificamerican0112-32.html |title=A New Path to Longevity |journal=Scientific American |date=2011 |accessdate=2016-11-20 |volume=306|doi=10.1038/scientificamerican0112-32 |pages=32–39}} 4. ^{{cite web |url=https://www.bloomberg.com/news/features/2015-02-12/does-a-real-anti-aging-pill-already-exist-|title = Does a Real Anti-Aging Pill Already Exist? Inside Novartis's push to produce the first legitimate anti-aging drug, Business Week, 2015|accessdate = November 20, 2016}} 5. ^{{Cite web |url=http://www.impactaging.com/editors.html |work=Aging |title=Editorial Board |accessdate=2016-11-20}} 6. ^{{Cite web |url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kccy20 |work=Cell Cycle |title=Editorial Board |accessdate=2016-11-20 |publisher=Taylor & Francis}} 7. ^{{Cite web |url=http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=pages&op=view&path%5B%5D=board |work=Oncotarget |title=Editorial Board |accessdate=2016-11-20}} 8. ^{{cite web |url=http://www.tandfonline.com/action/journalInformation?show=editorialBoard&journalCode=kcbt20 |work=Cancer Biology & Therapy |title=Editorial board |publisher=Taylor & Francis|accessdate=2016-11-20}} 9. ^{{cite web |url=http://www.nature.com/cdd/about.html |work=Cell Death & Differentiation |title=About the journal |accessdate=2016-11-20}} 10. ^1 {{cite web|last1=Beall |first1=Jeffrey |authorlink1=Jeffrey Beall |title=Oncotarget's Peer Review is Highly Questionable |url=https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ |website=Scholarly Open Access |accessdate=2016-11-20 |date=19 April 2016 |deadurl=yes |archiveurl=https://web.archive.org/web/20160420235706/https://scholarlyoa.com/2016/04/19/oncotargets-peer-review-is-highly-questionable/ |archivedate=20 April 2016 |df= }} 11. ^{{cite web|last1=Beall |first1=Jeffrey |authorlink1=Jeffrey Beall |title=LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals |url=https://scholarlyoa.com/individual-journals/ |website=Scholarly Open Access |accessdate=19 April 2016 |date=2016-11-20 |deadurl=yes |archiveurl=https://web.archive.org/web/20161202192038/https://scholarlyoa.com/individual-journals/ |archivedate=2 December 2016 |df= }} 12. ^{{cite web|url=https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ |title=Mikhail Blagosklonny's Journal Aging: A Review |website=Scholarly Open Access |date=6 December 2016 |accessdate=17 January 2017 |archiveurl=https://web.archive.org/web/20161224004259/https://scholarlyoa.com/2016/12/06/mikhail-blagosklonnys-journal-aging-a-review/ |archivedate=24 December 2016 |deadurl=yes |df= }} 7 : Living people|Russian medical researchers|Academic journal editors|Russian oncologists|New York Medical College faculty|Cancer researchers|Year of birth missing (living people) |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。